HIV prevention shots coming to your local pharmacy?

NCT ID NCT07210125

Ongoing Prevention Sponsor: Kelley-Ross & Associates, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a long-acting HIV prevention shot (lenacapavir) in community pharmacies is practical and acceptable. Seventy-five HIV-negative adults will receive the injection either twice a year or every three months, and researchers will track how many stay on the regimen and whether STI rates change. The goal is to see if pharmacies can help more people access this prevention option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenacapavir (long-acting injectable)
What this could lead to: If successful, this could show that community pharmacies are a convenient and effective place to deliver long-acting HIV prevention shots, potentially expanding access and reducing HIV infections.
What could go wrong: This is a small, single-center study with only 75 participants, so results may not apply broadly. It focuses on feasibility and acceptability, not on directly proving the drug prevents HIV.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

Kelley-Ross Pharmacy

Seattle, Washington, 98122, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.